Edited by Luke O'NeillElucidating the molecular mechanisms of the host-parasite interaction during red cell invasion by Plasmodium is important for developing newer antimalarial therapeutics. Recently, we have characterized a Plasmodium vivax tryptophan-rich antigen PvTRAg38, which is expressed by its merozoites, binds to host erythrocytes, and interferes with parasite growth. Interaction of this parasite ligand with the host erythrocyte occurs through its two regions present at amino acid positions 167-178 (P 2 ) and 197-208 (P 4 ). Each region recognizes its own erythrocyte receptor. Previously, we identified band 3 as the chymotrypsin-sensitive erythrocyte receptor for the P 4 region, but the other receptor, binding to P 2 region, remained unknown. Here, we have identified basigin as the second erythrocyte receptor for PvTRAg38, which is resistant to chymotrypsin. The specificity of interaction between PvTRAg38 and basigin was confirmed by direct interaction where basigin was specifically recognized by P 2 and not by the P 4 region of this parasite ligand. Interaction between P 2 and basigin is stabilized through multiple amino acid residues, but Gly-171 and Leu-175 of P 2 were more critical. These two amino acids were also critical for parasite growth. Synthetic peptides P 2 and P 4 of PvTRAg38 interfered with the parasite growth independently but had an additive effect if combined together indicating involvement of both the receptors during red cell invasion. In conclusion, PvTRAg38 binds to two erythrocyte receptors basigin and band 3 through P 2 and P 4 regions, respectively, to facilitate parasite growth. This advancement in our knowledge on molecular mechanisms of host-parasite interaction can be exploited to develop therapeutics against P. vivax malaria.Plasmodium vivax causes malaria in a huge human population in Southeast Asia and South America, thus affecting their socio-economic conditions. Although this parasite causes benign malaria, it can also cause complications, similar to Plasmodium falciparum, leading to death (1, 2). Because of the limited success to cultivate this parasite in the laboratory and very low parasitemia in P. vivax patients, the biology of this parasite is not explored in as much detail as that of P. falciparum. Not only is the parasite becoming more virulent, it is also showing resistance toward commonly used anti-malarial drugs. Furthermore, there is no vaccine available against this parasite. For effective control of this disease, newer anti-malarial drugs and vaccines need to be developed. Thus, identification of drug and vaccine targets is urgently needed. In this regard, the parasite molecules expressed at the merozoite stage and involved in erythrocyte invasion hold their significance as they have been proven to be the most effective drug or vaccine targets (3).Large numbers of host and parasite molecules need to interact with each other during erythrocyte invasion by the malarial parasite. Identification of all the host erythrocyte receptors and their respective parasi...